SynBio团队 | 华南理工 林章凛教授 机制概述：酸响应模块由两个质粒构成，一个质粒带有酸响应启动子（酸触发模块），表达4个针对不同立足点开关的触发RNA，另一个质粒带有4种立足 点开关（耐酸模块），分别表达4个与耐酸有关的基因。 细节如下： 研究首先在pCOLADuet-1质粒上构建了一个由4个酸响应启动子及其下游触发RNA表达框构成的酸触发模块。4个酸响应启动子表达产物为4种针对不同立 足点开关的触发RNA。为了保证立足点开关的表达效果，研究首先对 触发RNA 和 立足点开关 进行了基于红色荧光蛋白的筛选，筛选能在低pH情况下显著 增强下游基因翻译的触发RNA-立足点开关对，并在触发RNA-立足点开关不变的情况下，从酸响应启动子文库中，筛选了不同强度的酸响应启动子。 随后将不同强度的启动子、不同的触发RNA-立足点开关对、不同的耐酸基因合并成耐酸模块文库，耐酸基因因机制差异被分为4个功能组：质子消耗系统 （gadB、gadE、adiC、ybaS 和 rcsB）、蛋白质保护系统的伴侣（hdeB、degP、dps、spy 和 DS-YlHD），细胞膜修饰和氧化还原稳态系统（sthA、 cfa、osmY 和 ...

杭州民生健康药业股份有限公司 投资者关系活动记录表 编号：2025-008 证券代码： 301507 证券简称：民生健康 投资者关系活动 类别 □ 特定对象调研 □ 分析师会议 □ 媒体采访 □ 业绩说明会 □ 新闻发布会 □ 路演活动 □ 现场参观 ☑其他 （线上交流） 参与单位名称及 人员姓名 参与单位及人员详见附件 时间 2025 年 7 月 7 日至 7 月 10 日 地点 公司会议室 上市公司接待人 员姓名 董事会秘书 陈稳竹 证券事务代表 鲍蔚霞 证券事务助理 潘亦乐 投资者关系活动 主要内容介绍 一、公司介绍环节 由证券事务代表通过公司发展历史、业务结构、主要产品、 民生医药控股集团的业务板块等方面介绍了公司的基础情况。 随后，董事会秘书对公司各业务板块最新经营状况进行了补 充说明。 二、调研问答环节 1、问：观察到公司维矿类产品近年来持续增长，能否介绍 一下公司是如何实现增长的？ 答：维矿类产品作为公司主营业务，最近几期的报表都实现 了增长，主要是几方面的增长：线下药店终端，根据中康统计的 维生素矿物质补充剂下多维元素品类（不含孕妇）的产品数据， 公司主力产品 21 金维他®多维元素片（21） ...

梅花生物 20250709 摘要 公司近期完成了对协和发酵的收购，收购价格低于市场预期。这一收购补齐了 公司在医药氨基酸领域的短板，并新增了一部分产品业务管线，有助于应对海 外频发贸易壁垒，实现出海布局，从而开拓第二成长曲线。 梅花生物作为氨基酸行业龙头，受益于国内豆粕减量替代政策和动物蛋 白需求增长，尽管行业景气度当前较低，但公司现金流和造血能力依然 强劲，巩固了其市场地位。 公司完成对协和发酵的收购，低于市场预期，补齐了医药氨基酸短板， 新增产品线，有助于应对海外贸易壁垒，实现出海布局，开拓第二增长 曲线，提升盈利能力。 梅花生物重视股东回报，通过分红和持续回购兑现股东权益，过去三年 每年维持 20 亿以上的回购加分红金额，资本开支克制，盈利基础支持 持续回报。 公司业务以氨基酸产品为主，覆盖动物营养、食品味觉优化、人类医用 营养及胶体多糖，广泛应用于油气开采、食品添加、医疗美容等领域， 产品结构多元。 公司去年新增 60 万吨赖氨酸产能预计今年 10 月投产，并计划扩张苏氨 酸产能，但需结合市场情况决定，整体扩产节奏克制，销量持续增长， 强化龙头地位。 Q&A 梅花生物的主要业务和产品有哪些？ 梅花生物 ...

Group 1 - Daqing's agricultural product processing industry is experiencing high-quality development, with a projected revenue of 25.17 billion yuan in 2024 [1] - Lin Dian Wang Shi Food Processing Co., Ltd. has transformed from selling raw grains to producing pancakes, effectively mitigating market risks associated with grain sales [1] - The company operates five production lines, capable of producing 470-500 jin (approximately 235-250 kg) of pancakes daily, with sales covering the entire country [1] Group 2 - Daqing has established a significant rice and corn processing industry, with 31 large-scale rice processing enterprises and an annual processing capacity of 1.45 million tons [2] - Zhaoyuan rice has become one of the first geographical indications recognized by China and the EU, contributing to regional economic development [2] - The corn processing sector is also growing, with 10 large-scale enterprises and a notable output from Yipin, which has maintained over 4 billion yuan in revenue for three consecutive years [2] Group 3 - The dairy and meat industries in Daqing are thriving, with major companies like Yili and Mengniu leading the market [3] - Lin Dian County ranks among the top in dairy processing at the county level, while the meat industry is supported by a comprehensive supply chain from breeding to processing [4] - Daqing is developing a diversified agricultural industry system focusing on four main industries (dairy, meat, corn, rice) and eight specialty industries, enhancing the region's economic growth [4]

当快节奏生活与健康焦虑交织，当"千篇一律"的营养补充剂难以满足个性化需求，德国Selay以"自然为 本、科技为翼"的革新理念，重新定义膳食补充剂行业——从实验室到餐桌，从细胞健康到生活品质， Selay用每一粒胶囊、每一滴精华，为全球消费者打造"量身定制"的健康未来。 以"Selay精氨酸胶囊"为例，其核心成分玛咖、精氨酸、牡蛎肽和锌，通过科学配比显著改善体力与精 力，用户反馈显示，持续服用可显著提升生活质量。 在Selay的世界里，健康无需妥协——无论是追求极致效率的职场人，还是注重天然养生的家庭主妇； 无论是需要精准营养的银发族，还是渴望由内而外焕发光彩的年轻女性，都能找到属于自己的健康答 案。 Selay，不止于补充剂，更是一种生活态度——以科学之名，与自然共生，让健康成为触手可及的日 常。相信在未来，德国Selay将继续深化科研创新，拓展产品线，为消费者提供更精准、更高效的营养 解决方案，以科学为翼，以自然为根，守护每一个家庭的健康与幸福。 Selay坚信"千人千体"，针对不同人群推出个性化产品线，为中老年人设计的血糖平衡胶囊、芹菜籽胶 囊等，助力心血管与代谢健康；为女性呵护设计的麦角硫因饮、气血饮及 ...

Core Viewpoint - The article discusses the challenges and advancements in the industrialization of natural macromolecular active substances, highlighting a novel bioreactor developed to enhance fermentation processes for these substances [1][2][4]. Group 1: Challenges in Industrialization - Natural macromolecular active substances, such as polyamino acids, functional proteins, and microbial polysaccharides, face extraction difficulties due to their high molecular weight and complex conformations [1]. - The fermentation process of these substances is characterized by high viscosity, high oxygen demand, and high energy consumption, which complicates production [2][4]. - The accumulation of products during fermentation leads to high-viscosity non-Newtonian fluid characteristics, creating barriers that inhibit oxygen and nutrient metabolism, thus limiting yield improvements [1]. Group 2: Innovations in Bioreactor Technology - A new microbubble bioreactor platform has been developed using laser sintering 3D printing technology and computational fluid dynamics principles, aimed at overcoming the challenges of high-viscosity fermentation processes [2][4]. - This bioreactor design allows for the transition from macro to micro bubbles (less than 100 μm), significantly increasing the contact surface area between microorganisms and oxygen, thereby enhancing oxygen transfer efficiency by 120%-135% [4]. - The energy efficiency of the fermentation process is improved by 1.6 to 2.9 times compared to traditional bioreactors [4]. Group 3: Performance Improvements in Fermentation - The new bioreactor technology has been validated in a 7 L fermentation tank for the production of γ-polyglutamic acid (γ-PGA), achieving over a 40% increase in yield [5]. - The technology has also demonstrated versatility, with fermentation yields for other macromolecules such as mussel adhesive protein, panibacterial polysaccharide, welan gum, β-glucan, and ε-polylysine increasing by 79%, 58%, 39%, 50%, and 43% respectively [5]. Group 4: Implications for the Industry - This innovative research provides a reference and technical support for the efficient biosynthesis and industrial application of macromolecular active substances, as well as insights for enhancing fermentation processes in other synthetic biology products [7]. - The advancements in biomanufacturing are expected to contribute to the ongoing development of the synthetic biology industry, particularly in the context of green manufacturing and sustainable practices [7].

Core Business Strategy - The company will firmly implement the "231" industrial development strategy, focusing on "animal nutrition, food seasoning, and value chain extension" as its two core businesses [1] - The company aims to strengthen its animal nutrition, food additives, and seasoning sectors while promoting breakthroughs in three innovative fields: biomedicine, human nutrition and health, and plant nutrition [1] Financial Performance - In 2024, the company achieved operating revenue of 17.334 billion yuan and a net profit attributable to shareholders of 943 million yuan, representing a year-on-year growth of 39.12% [1] - In the first quarter of 2025, the company reported operating revenue of 4.039 billion yuan and a net profit attributable to shareholders of 474 million yuan, showing a year-on-year increase of 88.55% [1] Production Capacity and Market Position - The company ranks among the top producers globally in core products such as lysine, threonine, monosodium glutamate, and nucleotides, with both production capacity and technology levels leading the industry [1] - The company is investing in a 600,000-ton corn deep processing and cogeneration project in Xinjiang, which is currently under construction and will primarily produce small-volume amino acid products [2] Project Investments - The company plans to invest no more than 3.3 billion yuan in a 450,000-ton amino acid and supporting engineering project, with funding sourced from its own capital and bank loans, each accounting for approximately 50% [2] - The construction period for the amino acid project is expected to be 22 months [2] Market Conditions - The company acknowledges that product sales prices are influenced by raw material costs, market supply and demand, and industry competition, leading to some volatility [2] - The company is focused on enhancing product competitiveness through cost reduction and efficiency improvement, leveraging its large-scale production capabilities [2]

乐陵农商银行围绕乡村振兴和黄河流域高质量发展两条主线，通过创新业务产品，支持调味品、食品加 工等行业发展提质增效。目前共投放普惠型小微企业贷款17.97亿元，较年初增长4.21亿元。 "小微企业信用贷"激活企业发展动能 "为提升生产效率，我们企业工程师自行发明了两项专利，没想到这两项专利权不止能提高生产力，还 能用来办理质押贷款，咱农商行的服务是越来越高大上了。"乐陵市腾达辣椒制品有限公司负责人卞建 锋说。该公司利用两项专利在乐陵农商银行办理"知识产权质押贷"341万元，用于购进辣椒等调味品原 材料。 "知识产权质押贷"是乐陵农商银行在省联社的指导下，缓解小微企业融资难、支持实体经济发展、优化 营商环境的积极探索。企业办理该项业务既可享受利率优惠政策，同时也能享受相关财政补贴，可为企 业融资节约大量的生产成本。 将纳税信用转化可用资本 "前段时间农商银行秦经理给我打电话，说是可以根据我们的纳税额度办理优惠贷款，正赶上收购调料 需要资金，便试着申请了300万元贷款，没想到不到一周贷款就下来了。"乐陵市昌盛食品有限公司负责 人张国昌说。 昌盛食品位于乐陵市杨安镇调料市场，是一家以辣椒、葱、蒜等调味农产品加工销售为 ...

图为6月25日拍摄的新疆博尔塔拉蒙古自治州赛里木湖和连云港—霍尔果斯高速公路。新华社记者 赵嫣 摄 精河县托里镇克巴依西村，今年枸杞迎来了盛果期，种植户王磊正忙着给家中承包的枸杞摘果，他告诉记者，这是今年第一季枸杞的第二次摘 果，如果年景好，今年夏秋两季枸杞能够采摘7-8次，收入十分可观。 当地企业的锁鲜加工车就停在枸杞田边，刚从枝头采摘的枸杞大果直接进入车中进行锁鲜，避免了传统烘干加工方式所造成的口感和营养损 失，24小时后就可直送成都等地的订单商户，个大饱满的枸杞口感鲜甜，可以当作水果直接入口。 新华社新疆精河6月27日电（记者 赵嫣）盛夏的新疆西部，绚丽多彩，让人流连忘返，而更令人印象深刻的，是这里作为我国向西开放的 桥头堡所迸发出的勃勃生机。 在新疆博尔塔拉蒙古自治州精河县托里镇，6月如火骄阳下胖嘟嘟的橙红色枸杞沉甸甸压弯了枝头；沿着连霍公路西行一百多公里，一汪清澈 见底的湖水在阳光下熠熠发光，无数脚步停在了被称为"大西洋最后一滴眼泪"的赛里木湖边，游客们拍照留念、牵手漫步，静静感受那一 抹"赛里木蓝"；继续向西，两旁山谷草木葱郁，满眼绿意，来到伊犁哈萨克自治州霍城县，万亩薰衣草花田用盈盈的紫色诠释浪 ...

Core Viewpoint - The company, Zhejiang Shapuaisi Pharmaceutical Co., Ltd., has responded to the Shanghai Stock Exchange's inquiry regarding its 2024 annual report, particularly focusing on its investment in Shanghai Xinhong Pharmaceutical Co., Ltd. and the acquisition of shares in Yunnan Biological Valley Pharmaceutical Co., Ltd. [1][2] Investment in Shanghai Xinhong - The company, along with partners, invested a total of 460 million yuan in Shanghai Xinhong, with the company contributing 160 million yuan for a 34.7% stake [1][2] - The investment aims to leverage synergies between the company and Yunnan Biological Valley, which specializes in traditional Chinese medicine, particularly in cardiovascular disease treatments [2][4] Financial Performance of Yunnan Biological Valley - Yunnan Biological Valley reported revenues of 587 million yuan, 622 million yuan, and 516 million yuan over the last three years, with net losses of 49 million yuan, 12 million yuan, and 74 million yuan respectively [1][2] - The company recognized an investment loss of 7.22 million yuan related to its stake in Shanghai Xinhong due to Yunnan Biological Valley's losses in 2024 [1][2] Market Context - The increasing prevalence of cardiovascular diseases in China, with 330 million patients reported, highlights a growing market for related pharmaceuticals, particularly traditional Chinese medicine [4][3] - The company anticipates significant growth in the market for cardiovascular traditional Chinese medicine products, driven by an aging population and rising health awareness [4][3] Internal Decision-Making and Compliance - The company asserts that its investment decisions followed internal procedures compliant with the Company Law and relevant regulations, and the investment amount did not exceed 10% of its audited net assets [11][12] - Independent directors have confirmed that the investment process was conducted properly and did not harm the interests of the company or its minority shareholders [11][12] Other Investments - As of the end of 2024, the company reported long-term equity investments totaling 307 million yuan and other non-current financial assets of 20.4 million yuan, with additional investments in various pharmaceutical companies [12][15] - The company has engaged in risk investments, purchasing stocks worth 1.079 billion yuan and selling stocks worth 940 million yuan, resulting in a loss of 25 million yuan [12][15]